---

$23.39

-1.3000 ( -5.27% ) 303.8K

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Open	$23.39
Previous Close	$24.69
Volume	303.8K
Market Cap	$3.00B
Day Range	$23.36 - $25.41
52 Week Range	$7.91 - $28.72
Shares Outstanding	125.77M
Change %	-5.27%
Net Change	▼ -1.3000
Insider Ownership	-0.01%
Exchange	NYSE
Sector	Miscellaneous
Industry	None
IPO Year	2018
Country	United States
Underwriter	IPO Intelligence Only

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-06-07	Sale	-8400.00	Ribas Antoni
2024-03-29	Sale	-11551.00	Jarrett Jennifer
2024-03-20	Sale	-12153.00	Jarrett Jennifer
2024-02-28	Sale	-3900.00	Jaen Juan C.
2024-02-28	Sale	-24555.00	Jarrett Jennifer
2024-01-31	Buy	15238095.00	GILEAD SCIENCES, INC.
2024-01-25	Sale	-40000.00	Jaen Juan C.
2024-01-25	Sale	-8850.00	Azoy Alexander
2024-01-25	Sale	-40000.00	Jarrett Jennifer
2024-01-25	Sale	-100000.00	ROSEN TERRY J